UK scaleup Huma launches ‘Shopify-like’ platform for digital health tools

UK-based Huma has launched today the Huma Cloud Platform, a “Shopify-like” tool for the healthcare ecosystem to design, build, and launch digital health services.

“The digitalization of the healthcare ecosystem is a transformative force that is reshaping how we deliver and experience healthcare and how we conduct research,” Dan Vahdat, founder and CEO of Huma, told TNW.

Founded in 2011, Huma has been working with national healthcare providers and big pharma. Its technology powers digital clinical trials, remote patient monitoring (RPM), and companion apps for patient support.

Now, with the Huma Cloud Platform, the scaleup is bringing its technology to external customers.

Platform users will have access to a wide range of solutions, ranging from pre-built-modules, APIs, and GenAI capabilities to diagnostic and predictive AI algorithms, a marketplace, and no-code configuration of regulated disease management tools.

The platform will also support Huma’s existing regulated products. This includes the company’s Software as a Medical Device (SaMD) platform, which powers its RPM system and companion apps. Approved by regulators in the US, UK, EU, and Saudi Arabia, it’s the only device- and disease-agnostic tool of its kind to receive this status in combination with AI capabilities.

Huma says that this regulatory foundation can enable users of the Cloud Platform to reduce the time it takes to launch digital health projects at scale from years to days.

According to Huma, its technology has been used by more than 3,000 hospitals and clinics to date. The startup counts 1.8 millions active users across its products in over 70 countries. In 2023, it also partnered up with Google to explore GenAI capabilities.

Having doubled its revenue between 2022 and 2023, Huma aims to become profitable this year.

Alongside the launch, the London startup is also announcing a $80mn Series D round, which brings its total funding to over $300mn. Both existing and new investors backed the round, including AstraZeneca, Bayer, and Hitachi Ventures.